Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities research analysts at Leerink Swann reduced their Q2 2018 earnings estimates for shares of Thermo Fisher Scientific in a report released on Sunday, June 24th. Leerink Swann analyst P. Souda now forecasts that the medical research company will post earnings of $2.60 per share for the quarter, down from their previous forecast of $2.66. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q3 2018 earnings at $2.57 EPS and Q4 2018 earnings at $3.24 EPS.
Other research analysts have also issued reports about the stock. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Thursday, April 26th. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, May 16th. Finally, ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, June 20th. Two analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $224.38.
Thermo Fisher Scientific opened at $203.38 on Wednesday, according to MarketBeat. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.36. Thermo Fisher Scientific has a fifty-two week low of $170.07 and a fifty-two week high of $226.44. The stock has a market cap of $82.45 billion, a P/E ratio of 21.43, a PEG ratio of 1.50 and a beta of 1.11.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 25th. The medical research company reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The company had revenue of $5.85 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same period last year, the firm earned $2.08 earnings per share. The firm’s revenue was up 22.8% on a year-over-year basis.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 16th. Shareholders of record on Friday, June 15th will be given a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend is Thursday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is 7.17%.
In other news, Director C Martin Harris sold 206 shares of Thermo Fisher Scientific stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $214.43, for a total value of $44,172.58. Following the completion of the transaction, the director now owns 5,106 shares in the company, valued at $1,094,879.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $212.00, for a total transaction of $530,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 97,706 shares of company stock worth $21,125,673. Insiders own 0.49% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Icon Wealth Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $105,000. Johnson Financial Group Inc. increased its stake in shares of Thermo Fisher Scientific by 2,608.7% in the first quarter. Johnson Financial Group Inc. now owns 623 shares of the medical research company’s stock worth $129,000 after purchasing an additional 600 shares in the last quarter. Virtue Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $127,000. Premia Global Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $131,000. Finally, Private Capital Group LLC increased its stake in shares of Thermo Fisher Scientific by 57.3% in the first quarter. Private Capital Group LLC now owns 865 shares of the medical research company’s stock worth $179,000 after purchasing an additional 315 shares in the last quarter. Hedge funds and other institutional investors own 85.76% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.